Psychotic DisordersASESIDNCT03525054
Semantic and Syntactic Computerized Analysis of Free Speech
An observational study of Psychotic Disorders and Psychosis, run by University Hospital, Brest at 3 sites in France.
Trial summary
Subtle speech disorganization could be predictive of a transition to schizophrenia of ultra-high-risk patients. The aim of our longitudinal multicenter cohort study is to identify specific linguistic markers of the psychotic transition to validate a french predictive model of this transition using computerized speech… Read more about this study
- Who is it for?
- Ages 15 to 30 years
- Conditions the study is for
- Psychotic Disorders, Psychosis, Schizophrenia and Related Disorders
- How many people
- 215 participants
- Where
- 3 sitesFrance
- Study dates
- 18 May 2018to 2 May 2030
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 to 30 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: Help-seekers patients are recruited during two years from the early psychosis detection centers in Brest, France (CEVUP), Paris, France (CJAAD) and in Lausanne, Switzerland
Who may be able to join
- Major and/or minor from 15 to 30 years old
- Who alleged a suicidal gesture or idea or behavior that has repercussions in their emotional, social or professional life
- If patients receive neuroleptic treatment that impairs cognitive abilities, a one-week wash-out period will be scheduled prior to assessment.
- Affiliated with or beneficiary of a health insurance/social security system
- Able and willing to provide written informed consent
Who cannot join
- History of psychosis
- Risk of self-harm or violence not compatible with outpatient treatment
- QI<70 (WAIS)
- Neurological disorder or major health problem
- Impossibility to interrupt neuroleptic treatment for one week
- Refusal to participate
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
France3 sites, 3 recruiting
- Recruiting
CHRU de Brest
Brest, 29609
Michel WALTER, michel.walter@chu-brest.fr
- Not yet recruiting
Meunier Sophie
Caen
Sophie Meunier
- Recruiting
CH de SAINT ANNE
Paris, 750144
Marie-Odile KREBS, mo.krebs@ch-saint-anne.fr
About this study
Subtle speech disorganization could be predictive of a transition to schizophrenia of ultra-high-risk patients. The aim of our longitudinal multicenter cohort study is to identify specific linguistic markers of the psychotic transition to validate a french predictive model of this transition using computerized speech analysis techniques
Read the detailed description
Different scales allow identification of patients at ultra-high-risk to develop psychosis. The current challenge is to identify a predictive marker of transition to schizophrenia. Language disorders, which reflect psyche, could be one of these markers. Computerized speech analysis techniques such as Latent Semantic Analysis (LSA) have already proven their reliability in schizophrenia. These techniques reveal subtle speech disorganization that would be predictive of a clinical transition of ultra-high-risk psychotic patients. A combination of semantic and syntactic analysis could accurately predict the psychotic transition. The aim of our longitudinal multicenter cohort study is to validate this predicitve model in french language as well as identifying specific linguistic markers of the psychotic transition.
The initial report including the CAARMS is completed with an audio recording from the initial medical interview. The recording will be transcribed and analyzed by computer following the method of lemmatization and vectorial analysis (LSA). An analysis of the grammatical function (number of words, rate of the various grammatical functions) will also be performed. This first analysis will emerge linguistic markers correlated to transition to psychosis that we will use to construct a predictive model for transition to schizophrenia.
- Conditions
- Psychotic Disorders, Psychosis, Schizophrenia and Related Disorders, Schizophrenia Prodromal, Diagnosis, Psychiatric
- Keywords
- Psychotic Disorders, Diagnosis, Psychiatric, Schizophrenia Prodromal, Ultra High Risk, Prediction Of Psychosis, Machine Learning, Automated Language Analysis, Semantic Coherence, Syntaxic Complexity
- Medical subject headings
- Psychotic Disorders, Schizophrenia, Schizotypal Personality Disorder, Mental Disorders
What is being measured
The primary outcome is the main question the study is designed to answer.
Transition to schizophrenia
Determined from the CAARMS scale (COMPREHENSIVE ASSESSMENT OF AT RISK MENTAL STATES)
Measured: 2 years
Secondary outcomes (1)
Identification of patients at "ultra high risk " for developing schizophrenia
Determined from the CAARMS scale ( COMPREHENSIVE ASSESSMENT OF AT RISK MENTAL STATES)
Measured: Day 0
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 May 2018
- Study start18 May 2018
- Primary completion2 May 2030 (estimated)
- Study completion2 May 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Psychotic DisordersStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 215 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Brest
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03525054
- Sponsor's protocol ID
- ASESID (29BRC17.0198)
- Acronym
- ASESID
- Status last verified
- May 2026
- First submitted
- 26 Apr 2018
- Last updated
- 2 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Semantic and Syntactic Computerized Analysis of Free Speech
- ClinicalTrials.gov ID
- NCT03525054
- Acronym / sponsor ID
- ASESID / ASESID (29BRC17.0198)
- Conditions
- Psychotic Disorders, Psychosis, Schizophrenia and Related Disorders, Schizophrenia Prodromal, Diagnosis, Psychiatric
- Keywords
- Psychotic Disorders, Diagnosis, Psychiatric, Schizophrenia Prodromal, Ultra High Risk, Prediction Of Psychosis, Machine Learning, Automated Language Analysis, Semantic Coherence
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 215 participants (estimated)
- Lead sponsor
- University Hospital, BrestUniversity, hospital or other
- Study start
- 18 May 2018 (actual)
- Primary completion
- 2 May 2030 (estimated)
- Study completion
- 2 May 2030 (estimated)
- First posted
- 15 May 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Subtle speech disorganization could be predictive of a transition to schizophrenia of ultra-high-risk patients. The aim of our longitudinal multicenter cohort study is to identify specific linguistic markers of the psychotic transition to validate a french predictive model of this transition using computerized speech analysis techniques
Detailed description
Different scales allow identification of patients at ultra-high-risk to develop psychosis. The current challenge is to identify a predictive marker of transition to schizophrenia. Language disorders, which reflect psyche, could be one of these markers. Computerized speech analysis techniques such as Latent Semantic Analysis (LSA) have already proven their reliability in schizophrenia. These techniques reveal subtle speech disorganization that would be predictive of a clinical transition of ultra-high-risk psychotic patients. A combination of semantic and syntactic analysis could accurately predict the psychotic transition. The aim of our longitudinal multicenter cohort study is to validate this predicitve model in french language as well as identifying specific linguistic markers of the psychotic transition.
The initial report including the CAARMS is completed with an audio recording from the initial medical interview. The recording will be transcribed and analyzed by computer following the method of lemmatization and vectorial analysis (LSA). An analysis of the grammatical function (number of words, rate of the various grammatical functions) will also be performed. This first analysis will emerge linguistic markers correlated to transition to psychosis that we will use to construct a predictive model for transition to schizophrenia.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 15 to 30 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- Help-seekers patients are recruited during two years from the early psychosis detection centers in Brest, France (CEVUP), Paris, France (CJAAD) and in Lausanne, Switzerland
Key inclusion criteria (5 listed)
- Major and/or minor from 15 to 30 years old
- Who alleged a suicidal gesture or idea or behavior that has repercussions in their emotional, social or professional life
- If patients receive neuroleptic treatment that impairs cognitive abilities, a one-week wash-out period will be scheduled prior to assessment.
- Affiliated with or beneficiary of a health insurance/social security system
- Able and willing to provide written informed consent
Key exclusion criteria (6 listed)
- History of psychosis
- Risk of self-harm or violence not compatible with outpatient treatment
- QI<70 (WAIS)
- Neurological disorder or major health problem
- Impossibility to interrupt neuroleptic treatment for one week
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Transition to schizophrenia
Time frame: 2 years
Determined from the CAARMS scale (COMPREHENSIVE ASSESSMENT OF AT RISK MENTAL STATES)
1 secondary outcome
Identification of patients at "ultra high risk " for developing schizophrenia
Time frame: Day 0
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jun 2026.
Related trials for Psychotic Disorders
Recruiting
Supporting Patients by Family Education in Psychotic Illness: A Prospective Cohort Study
Psychotic Disorders, Family Members
RecruitingObservational study
The ATP Project (Antipsychotic-TEP-Psychosis)
First Episose Psychosis, Metabolic Disease
RecruitingPhase 2
Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia
Schizophrenia
RecruitingPhase 2
NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia
Schizophrenia
Not yet recruiting
Cognitive Neurocomputational Task Reliability and Clinical Applications Consortium: Study 2
SCHIZOPHRENIA 1 (Disorder), Schizo Affective Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Psychotic Disorders and Psychosis, run by University Hospital, Brest at 3 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Christophe LEMEY, Doctor (02 98 01 52 06, christophe.lemey@chu-brest.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Transition to schizophrenia (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jun 2026.